UBS Maintains Buy on Legend Biotech, Raises Price Target to $49
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $31 to $49.
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $31 to $49.